Interest in reliable biomarkers of Alzheimer disease, the leading cause of dementia, has been fuelled by challenges in diagnosing the disease and monitoring disease progression as well as the response to therapy. A range of ocular manifestations of Alzheimer disease, including retinal and lens amyloid-beta accumulation, retinal nerve fiber layer loss, and retinal vascular changes, have been proposed as potential biomarkers of the disease. Herein, we examine the evidence regarding the potential value of these ocular biomarkers of Alzheimer disease.
BACKGROUND
Alzheimer disease (AD) is a neurodegenerative disorder that was first described more than a century ago. It is the most common form of dementia, affecting approximately 35.6 million people worldwide in 2010 and an estimated 115 million people by the year 2050. 1, 2 Advances in the treatment and prevention of AD have been hampered by challenges in diagnosing the disease, as it shares many symptoms and clinical signs in common with other forms of dementia, including Lewy-body disease, frontotemporal dementia, and vascular dementia. Moreover, detection of the earliest stages of the disease is confounded by the overlap with age-related cognitive decline. Definitive diagnosis of AD is typically made post mortem through the histopathological analysis of brain tissue. The hallmarks of AD are the accumulation of extracellular plaques comprised amyloid-beta (Aβ) and intraneuronal neurofibrillary tangles comprised hyperphosphorylated tau protein, with associated neurodegeneration (Fig. 1) .
Positron emission tomography (PET) imaging of the brain utilizing radiotracers with affinity for Aβ, and more recently tau, are useful tests to assist in the diagnosis of AD. 2, 3 Positron emission tomography studies have demonstrated that amyloid accumulation predates the onset of clinical symptoms by as long as 15 to 20 years, highlighting the potential for amyloid imaging in preclinical diagnosis of the disease. 4, 5 Unfortunately, PET scans are costly, difficult to access, involve the use of ionizing radiation, and have relatively limited spatial resolution (2-10 mm) with implications for disease monitoring. Cerebrospinal fluid biomarkers, including Aβ and tau, have value in confirming a clinical diagnosis of AD, but alone they have limited sensitivity and specificity and necessitate lumbar puncture, an invasive procedure that is not appropriate for screening at a population level. 5, 6 It has been postulated that diagnostic uncertainty and the inclusion of subjects with late-stage disease have contributed to the high failure rate-approaching 90%-of clinical drug trials for AD. 2, 7, 8 Until recently, hopes for disease modifying therapies for AD have been distant. While 2 phase III clinical trials of the anti-Aβ antibody solanezumab for mild-to-moderate AD failed to meet their primary endpoints, a recent subgroup analysis suggests that the therapy may be effective when used early in the course of AD. 9, 10 When data for all trial participants with mild AD were pooled, 3 of 6 prespecified endpoints were met and cognitive decline was slowed by 34%. 10 A more recent double blind placebo-controlled phase Ib randomized trial of monthly infusions of aducanumab, a human monoclonal antibody with specificity for aggregated Aβ, in individuals with mild and prodromal AD demonstrated statistically significant dose-and time-dependent reductions in brain Aβ levels, measured by florbetapir PET imaging. In the highest dose group (10 mg/kg), PET-Aβ burden scores had reduced to near normal by the 54-week time point.
11
In comparison, subjects in the placebo group showed no significant change in PET-Aβ burden. While the study was not powered to detect clinical change, posthoc analysis indicated that subjects exhibiting a reduction in PET-Aβ burden (>1 standard deviation of the mean PET standard uptake value ratio relative to placebo-treated subjects) demonstrated a stabilization of cognitive decline on 2 clinical scales (Clinical Dementia Rating-Sum of Boxes and the mini-mental state examination). Brain vasogenic edema occurred in a dose-dependent manner and was observed in 47% of subjects treated with the highest dose of the antibody. 11 Long-term extension of the study and 2 phase III clinical trials are underway. Several other novel approaches to the treatment of AD, including Aβ vaccines and inhibitors of the enzyme involved in Aβ production (beta-secretase 1), are undergoing clinical trials. 12 It has been posited that therapies with relatively modest effects on Aβ accumulation may be sufficient to alter the trajectory of disease progression if commenced in the early stages of the disease. Modeling suggests that interventions that delay the onset of clinically manifest AD by 5 years could reduce the incidence of the disease by almost half. 13 The potential for effective therapies for AD has reinvigorated interest in the identification of novel biomarkers of AD to facilitate preclinical diagnosis, to confirm clinically diagnosed AD and to monitor disease progression, as well as the response to therapy. The identification of an accurate biomarker of disease burden that can be measured at the point of care would transform clinical trials of new therapies and accelerate the translation of research findings into the management of people with AD. This review examines the evidence for putative ocular biomarkers of AD.
RETINAL BIOMARKERS
The retina develops as an outpouching of the forebrain and is considered as part of the central nervous system. Emerging evidence suggests that some of the hallmark pathological features of AD in the brain may manifest in the retina. Advances in ocular imaging technologies mean that it is now possible to image the retina in vivo at resolutions of several microns-at least an order of magnitude higher than can be achieved with conventional brain imaging techniques such as magnetic resonance imaging.
14 Accordingly, the identification of retinal manifestations of AD may be proven useful for diagnosis and monitoring of progression. 
Retinal amyloid-beta accumulation
The search for key pathological features of AD in the retina has spanned more than 3 decades, and the evidence remains mixed. Numerous studies of transgenic mouse and rat models of AD have identified retinal accumulation of Aβ. [15] [16] [17] [18] [19] Indeed, Aβ deposition has been identified in most retinal layers, including the retinal ganglion cell (RGC) and nerve fiber layers, the inner plexiform layer as well as the outer retina. 20 Studies of the Octodon degus, a South-American rodent that exhibits brain Aβ and tau pathology as well as age-related cognitive decline, also demonstrate the accumulation of Aβ and phosphorylated tau in the retina, chiefly in the nerve fiber and ganglion cell layers. 21 Several AD model mouse studies have demonstrated that retinal Aβ accumulates in an age-dependent manner and correlates with the burden of amyloid plaques in the brain. 16, 17, 20 Interestingly, work in double transgenic mice (APP SWE /PS1ΔE9) harboring mutations in 2 genes implicated in early onset AD demonstrated the appearance of retinal amyloid plaques prior to brain plaques.
While useful, animal models of AD have limitations, and the translational relevance of findings in these model systems is a matter of ongoing debate.
Studies of human retina have been less definitive. While postmortem examinations of retinal tissue from people with histopathologically confirmed AD have repeatedly demonstrated RGC degeneration and loss, several studies have found either no evidence of Aβ accumulation [22] [23] [24] [25] or Aβ deposition restricted to subretinal pigment epithelial deposits (drusen and basal linear deposits). [26] [27] [28] [29] Most of these studies were performed on retinal tissue sections, and it may be that sparsely distributed amyloid plaques may be missed with this approach. While hyperphosphorylated tau was identified in retinal sections of 5 of 6 people with AD in 1 study, no fibrillar tau aggregates were detected. 30 Other studies have also found no evidence of fibrillar tau aggregates in human retinal sections. 23, 25 In contrast, a number of recent studies of Aβ in human retinal wholemounts have confirmed the findings of the animal studies. Koronyo-Hamaoui and colleagues examined retinal tissue from 8 humans with clinically diagnosed and histopathologically confirmed AD and identified amyloid plaques ranging in size from 1 to 10 μm in all cases but not in AD-free control retinas (n = 5). 20 Amyloid plaques were identified with a range of well-accepted markers, including curcumin and Thioflavin S and 2 monoclonal antibodies with binding specificities for different epitopes of Aβ. Furthermore, amyloid plaques were identified in the retinas of all subjects with presumed early-stage AD (n = 5, ascertained on the basis of antemortem clinical findings and postmortem neuropathology). 20 Small studies by other groups have demonstrated elevated levels of Aβ (the isoform of Aβ that is enriched in neocortical deposits 31 ) and amyloid plaques in the retinas of people with histopathologically confirmed AD. 19, 32 Another study of retinal wholemounts from 5 subjects with confirmed AD and 5 age-matched controls demonstrated substantial accumulation of Aβ in the retinas of all those with AD and no or minimal staining in control retinas. 33 To examine the potential of noninvasive retinal imaging for Aβ, Koronyo-Hamaoui et al. administered intravenous curcumin to AD model mice (APP SWE / PS1ΔE9) and performed in vivo fluorescent imaging with a rodent retinal camera. 20 Curcumin (diferuloylmethane) is a lipophilic polyphenol from the rhizomes of the turmeric plant (Curcuma longa) and a fluorophore that has long been known to bind with high affinity to Aβ. 34 Curcumin fluorescence was clearly visible in AD model mice but not in wild-type control mice, and curcumin-labeled retinal plaques were colabeled ex vivo with monoclonal antibodies with specificity for Aβ. 20 Human clinical trials of curcumin for Aβ retinal imaging in AD are currently underway (Australian New Zealand Clinical Trials Registry: ACTRN12613000367741). The trials utilize a proprietary formulation of curcumin, with higher oral bioavailability than unmodified curcumin, and fluorescence imaging is performed with confocal scanning laser ophthalmoscopy. 34 The abstract of an oral presentation by the group reported the findings of a pilot study of 40 patients with ADthe technique differentiated subjects with AD from those without with high sensitivity (100%) and specificity (80.6%). 35 Retinal Aβ load was strongly correlated with brain amyloid plaque burden by PET imaging (Pittsburgh compound B) . 35 These findings have not yet been reported in the peer-reviewed literature.
Recent work suggests that it may be possible to detect retinal Aβ noninvasively without the need for exogenous fluorophores. Investigators used hyperspectral imaging (HSI) microscopy to examine cells and tissues for Aβ. 36 Hyperspectral imaging microscopy is an optical imaging technique that exploits the fact that the spectral properties of the light reflected from a tissue are influenced by the composition of the tissue. When a tissue is imaged with numerous different wavelengths of light, a spectral signature (reflectance as a function of wavelength) is generated that is indicative of its composition. The investigators first used dark field HSI microscopy to examine a neuronal cell line (SHSY-5Y) in culture following the addition of soluble Aβ . 36 They discovered that cells containing aggregated Aβ scatter short wavelength light when imaged across visible and near infrared wavelengths (400-1000 nm)-this was manifested as an attenuation of the intensity of the reflected light detected by the microscope camera that was most pronounced at shorter wavelengths (in the 480-520 nm range; Fig. 2 ). The scattering effect of aggregated Aβ has been attributed primarily to Rayleigh scattering, whereby light is scattered by particles much smaller than the wavelengths of the illuminating light. The efficiency of Rayleigh scattering increases as the wavelength of the illuminating light decreases; hence, the effect is most apparent at shorter wavelengths. The investigators demonstrated the spectral signature of aggregated Aβ in retinal tissue from AD model mice (APP/PS1), as well as from postmortem brain and retinal samples from people with confirmed AD. 36 Mirroring the curcumin studies, the retinal signal for Aβ was detected prior to its appearance in the brain in transgenic mice and the signal correlated with the brain amyloid burden. 36 The same group has recently demonstrated the in vivo detection of a retinal spectral signature of Aβ in transgenic AD model mice by using a modified endoscope applied to the corneal surface. 37 The technique was sensitive enough to longitudinally monitor the retinal accumulation of aggregated Aβ over a 6-month period. Thus, the spectral signature of aggregated Aβ has been demonstrated in cell culture, in retinal and brain tissue samples from AD mice and humans, as well as in retinal imaging of live AD mice, using 2 different imaging systems. Nevertheless, the specificity of the observed spectral signature needs to be established as other molecular aggregates could generate similar patterns of Rayleigh scattering. Whether noninvasive hyperspectral retinal imaging can be adapted for in vivo Aβ retinal imaging in humans and whether this serves as a useful biomarker of AD remain to be seen.
Retinal ganglion cell and nerve fiber layer loss
It has long been known that AD is associated with the loss of RGCs and thinning of the retinal nerve fiber layer. An early postmortem study revealed diffuse axonal degeneration in the optic nerves of 8 of 10 individuals with AD, with the loss of between 15% and 80% of axons. 23 Retinal ganglion cell loss and diminution of the nerve fiber layer were identified in 3 of the 4 retinas examined, and reactive gliosis was evident in 2 retinas. Histological studies of retinal wholemounts have confirmed extensive loss of neurons in the ganglion cell layer at all retinal eccentricities in individuals with AD, relative to controls, and significant increases in astrocyte numbers were noted in the ganglion cell layer of 6 of 11 individuals with AD. 38, 39 Some evidence points to increased susceptibility of medium-to-large RGCs in AD. The preferential loss of large diameter axons in the optic nerve and RGCs with the largest somata in histologic studies add some support to this hypothesis. 22, 23 A study of melanopsin RGCs (mRGCs), photosensitive ganglion cells that play roles in circadian photoentrainment, has demonstrated a significantly greater loss of these cells in people with AD than in those without, implicating the loss of these cells in circadian disturbances in AD. 33 Interestingly, prominent Aβ accumulation was noted within and around mRGCs in retinas from people with AD (n = 5) but not in controls (n = 5). The utility of this observation for the development of a biomarker of AD is doubtful, however, given the relative rarity of mRGCs (1-2% of all RGCs) and a lack of methods to enumerate them in vivo.
Numerous clinical studies using optical coherence tomography (OCT) have demonstrated retinal nerve fiber layer loss in individuals with AD, and changes are apparent relatively early in the course of the disease. 33, [40] [41] [42] [43] [44] [45] [46] Several patterns of retinal nerve fiber layer loss have been reported in AD, including sectoral loss of retinal nerve fibers in the superior retina, 33 ,47 the superior and nasal retina, 48 or the superior and inferior retina. 41, 42, 49 A systematic review of OCT studies of individuals with either clinically diagnosed AD or mild cognitive impairment demonstrated significant reductions in mean retinal nerve fiber layer thickness in both groups (702 AD eyes and 214 mild cognitive impairment eyes) relative to age-matched healthy controls (790 and 421 control eyes, respectively). 50 Subgroup analysis demonstrated significant reductions in nerve fiber layer thickness for studies using either temporal domain OCT or spectral domain OCT. All of the studies included in the review were cross-sectional, and case definition was based on clinical criteria alone. No clear correlation between retinal nerve fiber layer loss and the severity of AD has been demonstrated. 41, 43, 45, 50 Retinal nerve fiber layer thinning is nonspecific, and similar reductions occur in other neurodegenerative diseases, including glaucoma, Parkinson disease, and multiple sclerosis. Accordingly, the clinical utility of retinal OCT in the diagnosis and monitoring of AD remains in question. Changes in RGC function, as measured by pattern electroretinogram, have been reported in a number of studies (reduced amplitude and increased implicit times); however, changes are not specific to AD. 49, [51] [52] [53] The loss of RGCs and retinal nerve fiber layer thickness in AD are unlikely to be a consequence of transsynaptic degeneration induced by neurodegeneration in visual centers of the brain as the lateral geniculate nucleus and visual cortex appear to be relatively spared in the disease. 22 Instead, experimental work points a toxic effect of Aβ on RGCs. 54 Intravitreal injection of Aβ (either Aβ or Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) in rats induced oxidative stress and RGC apoptosis, in a dose-and time-dependent manner. 55 Of interest, Aβ has been implicated in RGC apoptosis induced by intraocular pressure elevation in experimental models of glaucoma in rodents. 55, 56 Amyloid-beta was found to colocalize with apoptotic RGCs, and the inhibition of different aspects of the Aβ formation and aggregation pathway reduced RGC loss in the context of experimental glaucoma. 55 The extent to which Aβ is involved in human glaucoma remains to be established. These findings may have relevance for the specificity of retinal Aβ imaging as a biomarker for AD.
Retinal vascular biomarkers
Given the anatomical and physiological similarities between the retinal and cerebral vasculature, a number of studies have examined associations between retinal vascular parameters and AD. 57 Amyloid-beta is known to accumulate in blood vessel walls in AD, and it has been proposed that cerebrovascular disease may contribute to AD. 58 Retinal arteriolar narrowing has been associated with vascular dementia in numerous studies, but the evidence for an association with AD is mixed. 47, 59, 60 Furthermore, venular narrowing and decreased arteriolar and venular fractal dimensions (a measure of retinal vascular network complexity) have been reported in some studies, 47, 61, 62 but not in others. 59 Alzheimer disease has also been variously associated with increased and reduced venular tortuosity. 61, 62 Given these mixed findings and outstanding questions regarding a direct vascular contribution to the pathogenesis of AD, it is apparent that there are presently no clinically useful retinal vascular biomarkers of AD.
LENS BIOMARKERS
The crystalline lens is susceptible to age-related degenerative changes, including the aggregation of insoluble proteins, which contributes to cataract formation. 63 Several studies have identified Aβ in rodent, monkey, and human lenses. 64, 65 Recent work has demonstrated the accumulation of the Aβ 1-40 and Aβ isoforms in the lenses of people with AD at concentrations comparable with those in brain. 65 This is in keeping with the observation that Aβ accumulation may occur in a variety of tissues outside the central nervous system, including skin and blood vessels (reviewed in Khan and Alkon). 66 Postmortem studies revealed equatorial supranuclear cataracts in all those with confirmed AD (n = 9) but not in lenses from matched controls (n = 8). 65 Amyloid-beta was enriched in cataractous regions, and binding interactions were demonstrated between Aβ and the lens protein αβ-crystallin. Lenticular accumulation of Aβ and supranuclear cataracts have been observed in Down syndrome, a condition in which triplication of chromosome 21 includes the amyloid precursor protein gene (cleavage of amyloid precursor protein gives rise to Aβ) and which is associated with early onset AD. 67 In addition, cataracts have been reported in transgenic mice overexpressing Aβ. 68 It is notable that other studies have failed to identify Aβ in human lenses. 25, 69 Differences in tissue processing and Aβ detection methods may account for the discrepancies between studies. 25 Nevertheless, the extent to which Aβ accumulates in the lens and the temporal sequence of this relative to brain Aβ accumulation in AD remain in question. 58 van Wijngaarden et al.
In vivo imaging of lens Aβ has been demonstrated by 1 group of investigators in 2 small clinical studies of humans with AD. 70, 71 Investigators used a fluorescent ligand (aftobetin hydrochloride) with affinity for Aβ and demonstrated ocular penetration following topical application of an ointment. Fluorescence imaging was used to measure the intensity and decay of fluorescence (fluorescence lifetime imaging) in the lens following ointment administration. The imaging technique predicted the clinical diagnoses of 20 patients with AD and 20 healthy control subjects with a sensitivity of 85% and a specificity of 95%. 70 Clinical prediction in this small study was superior with this method than with Aβ-PET imaging (florbetapir F18), and the fluorescent signal correlated with brain Aβ load as estimated by PET. 70 If replicated in a larger study, including a range of subjects with differing disease severity, then this approach may hold promise as a useful biomarker of AD. An obvious limitation of this approach is that it will not be useful in patients who have undergone cataract surgery.
CONCLUSIONS
In an era of emerging therapies for AD, there is renewed interest in the identification of a reliable biomarker of the disease that can be measured at the point of care. While preliminary evidence suggests that Aβ may accumulate in the lenses and retinas of people with AD, no ocular biomarker of the disease has yet been clinically validated. While approaches to in vivo measurement of ocular Aβ have been tested, studies have been small and results have either not yet been subjected to peer review, as is the case for curcumin retinal Aβ imaging, or reproduced by other groups, as is the case for lens amyloid imaging. The time course of Aβ accumulation in these tissues in humans is not well characterized, and correlations between ocular and brain Aβ loads are not known. Changes in retinal nerve fiber layer thickness, as quantified by OCT, and measures of reduced RGC function have been widely observed in AD; however, the clinical utility of these findings is limited by the lack of specificity of the changes and an apparent lack of correlation with disease severity. Similarly, there is insufficient evidence to support the use of retinal vascular biomarkers of AD.
In summary, while recent work points to the potential of ocular biomarkers in AD, further evidence is needed. In the event that an ocular biomarker is proven useful, it is likely that eye health professionals will become engaged in screening for and monitoring of AD. The work of optometrists and ophthalmologists regularly entails screening for ocular manifestations of systemic diseases and thus detecting biomarkers of AD would constitute a logical extension of their scope of practice. Accordingly, the burgeoning epidemic of AD may thus have significant implications for eye health service delivery in future.
